tiprankstipranks
Trending News
More News >
Eupraxia Pharmaceuticals (TSE:EPRX)
TSX:EPRX
Advertisement

Eupraxia Pharmaceuticals (EPRX) AI Stock Analysis

Compare
36 Followers

Top Page

TSE:EPRX

Eupraxia Pharmaceuticals

(TSX:EPRX)

Select Model
Select Model
Select Model
Neutral 45 (OpenAI - 4o)
Rating:45Neutral
Price Target:
Eupraxia Pharmaceuticals' overall score reflects its challenging financial position with no revenue and ongoing net losses. While recent positive trial results and operational progress are encouraging, the company's reliance on external financing and high liabilities pose significant risks. Technical indicators suggest some positive momentum, but valuation challenges persist due to lack of profitability. The strengthened financial position through capital raise is a mitigating factor but does not offset the underlying financial instability.
Positive Factors
Operational Progress
The advancements in the RESOLVE trial demonstrate Eupraxia's capability to progress its drug pipeline, potentially leading to future product commercialization and revenue generation.
Capital Raise
The capital raise enhances Eupraxia's liquidity, providing the necessary funds to continue operations and advance clinical trials, reducing immediate financial risk.
Positive Trial Results
Promising trial results for EP-104GI indicate potential for successful treatment options, which could lead to regulatory approvals and market entry, strengthening the company's competitive position.
Negative Factors
Financial Instability
The lack of revenue and persistent net losses highlight financial instability, which could hinder long-term sustainability and limit the ability to fund ongoing operations without external financing.
Cash Flow Challenges
Negative cash flows indicate reliance on external funding, posing risks to operational continuity and financial flexibility, potentially affecting the company's ability to invest in growth opportunities.
High Liabilities
High liabilities can strain financial resources and limit strategic options, potentially affecting the company's ability to respond to market changes or invest in new projects.

Eupraxia Pharmaceuticals (EPRX) vs. iShares MSCI Canada ETF (EWC)

Eupraxia Pharmaceuticals Business Overview & Revenue Model

Company DescriptionEupraxia Pharmaceuticals (EPRX) is a clinical-stage biotechnology company focused on developing innovative drug products for the treatment of chronic diseases. The company's primary focus is on creating long-acting formulations that aim to provide sustained therapeutic effects, particularly in areas with significant unmet medical needs such as osteoarthritis and other pain-related conditions. Eupraxia's lead product candidate is EP-104IAR, a proprietary sustained-release formulation intended to alleviate pain and improve joint function in patients with osteoarthritis.
How the Company Makes MoneyEupraxia Pharmaceuticals primarily generates revenue through the development and potential commercialization of its drug candidates. The company is focused on advancing its lead product candidates through clinical trials, seeking regulatory approval, and ultimately bringing these products to market. Revenue is expected to be derived from product sales, licensing agreements, and strategic partnerships. Eupraxia may engage in collaborations with larger pharmaceutical companies to co-develop or commercialize its products, thus gaining access to additional resources and market channels. However, as a clinical-stage company, Eupraxia's current revenue is likely limited and largely dependent on funding from investors, grants, or milestone payments from partnerships until its products receive regulatory approval and can be commercialized.

Eupraxia Pharmaceuticals Financial Statement Overview

Summary
Eupraxia Pharmaceuticals faces significant financial challenges, marked by zero revenue and ongoing net losses. Despite a strong cash position, reliance on external financing and persistent cash burn due to negative operating cash flows indicate financial instability.
Income Statement
5
Very Negative
Eupraxia Pharmaceuticals has recorded consistent negative revenue growth with no reported revenue over the years, resulting in substantial net losses. Gross profit and EBIT margins are negative, indicating significant operating challenges without revenue generation.
Balance Sheet
20
Very Negative
The company maintains a strong cash position relative to its liabilities, evidenced by a high equity ratio. However, the debt-to-equity ratio is skewed by negative equity in past years, and high liabilities pose a risk, despite recent improvements in stockholders' equity.
Cash Flow
15
Very Negative
Persistent negative operating and free cash flows highlight liquidity challenges. Cash flow from financing has been the main source of liquidity, indicating reliance on external funding. Free cash flow growth remains negative, suggesting ongoing cash burn.
BreakdownTTMDec 2024Dec 2023Dec 2022Dec 2021Dec 2020
Income Statement
Total Revenue0.000.000.000.000.000.00
Gross Profit-57.51K-235.25K-209.91K-193.27K-111.53K-116.81K
EBITDA-25.89M-33.72M-37.40M-22.14M-21.96M-2.01M
Net Income-26.22M-34.94M-37.39M-23.26M-22.99M-4.00M
Balance Sheet
Total Assets29.23M50.24M26.72M25.88M31.22M1.45M
Cash, Cash Equivalents and Short-Term Investments27.45M33.10M19.34M24.74M29.90M150.13K
Total Debt52.77K103.31K10.45M10.55M9.56M12.77M
Total Liabilities2.20M4.46M25.55M14.51M11.67M23.12M
Stockholders Equity28.60M33.40M2.22M12.86M20.39M-21.21M
Cash Flow
Free Cash Flow-30.14M-30.10M-28.02M-19.08M-15.07M-403.93K
Operating Cash Flow-29.88M-29.99M-27.92M-18.78M-14.64M-403.93K
Investing Cash Flow-237.41K-75.16K-99.03K8.70M-14.45M24.62K
Financing Cash Flow23.06M45.78M27.84M13.52M49.92M-626.64K

Eupraxia Pharmaceuticals Technical Analysis

Technical Analysis Sentiment
Positive
Last Price7.99
Price Trends
50DMA
7.46
Positive
100DMA
6.75
Positive
200DMA
5.80
Positive
Market Momentum
MACD
0.21
Negative
RSI
55.21
Neutral
STOCH
30.51
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For TSE:EPRX, the sentiment is Positive. The current price of 7.99 is above the 20-day moving average (MA) of 7.68, above the 50-day MA of 7.46, and above the 200-day MA of 5.80, indicating a bullish trend. The MACD of 0.21 indicates Negative momentum. The RSI at 55.21 is Neutral, neither overbought nor oversold. The STOCH value of 30.51 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for TSE:EPRX.

Eupraxia Pharmaceuticals Peers Comparison

Overall Rating
UnderperformOutperform
Sector (51)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
69
Neutral
1.40B53.831.71%31.72%
55
Neutral
3.34B24.92-12.83%10.20%
47
Neutral
590.95M1,744.120.05%13.82%
45
Neutral
C$291.81M-158.24%
43
Neutral
144.24M
51
Neutral
$7.86B-0.30-43.30%2.27%22.53%-2.21%
* Healthcare Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
TSE:EPRX
Eupraxia Pharmaceuticals
7.99
4.44
125.07%
TSE:ARCH
Arch Biopartners
1.40
-0.37
-20.90%
TSE:MDNA
Medicenna Therapeutics Corp
0.96
-0.93
-49.21%
FENC
Fennec Pharmaceuticals
9.04
4.04
80.80%
NGENF
NervGen Pharma
2.35
0.45
23.68%
TSE:DRUG
Bright Minds Biosciences
74.89
73.42
4994.56%

Eupraxia Pharmaceuticals Corporate Events

Executive/Board ChangesPrivate Placements and FinancingBusiness Operations and StrategyFinancial Disclosures
Eupraxia Pharmaceuticals Reports Strong Q4 2024 Results and Operational Progress
Positive
Mar 20, 2025

Eupraxia Pharmaceuticals announced its fourth quarter 2024 financial results, highlighting significant advancements in its RESOLVE trial for eosinophilic esophagitis and a strengthened financial position with a C$44.5 million capital raise. The company reported a reduced net loss due to lower research and development costs and increased cash reserves, positioning it well for continued operations into 2026. Key operational updates included leadership changes and positive trial data, which may enhance its industry standing and stakeholder confidence.

Product-Related Announcements
Eupraxia Pharmaceuticals Reports Promising Trial Results for Eosinophilic Esophagitis Treatment
Positive
Feb 25, 2025

Eupraxia Pharmaceuticals has announced positive results from its RESOLVE Phase 1b/2a trial for EP-104GI, a treatment for eosinophilic esophagitis. The trial showed significant improvements in symptom relief and tissue health, particularly in Cohort 6, with no serious adverse events reported. The data suggests that higher doses and increased esophageal coverage of EP-104GI lead to better outcomes, encouraging further exploration of its potential benefits.

Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: Apr 23, 2025